Edition:
United Kingdom

JCR Pharmaceuticals initiates phase 3 clinical trial of JR-141 for Hunter Syndrome


Thursday, 9 Aug 2018 

Aug 9 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says the company announced today the initiation of a Phase 3 clinical trial of JR-141 in Japan .JR-141 is a blood-brain-barrier (BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR’s proprietary BBB technology, is applied . 

Company Quote

6150.0
50.0 +0.82%
7:00am BST